Rapport Therapeutics (NASDAQ:RAPP) Stock: Insider Abraham Ceesay Sells 2,210 Shares

Rapport Therapeutics, Inc. (NASDAQ:RAPP) CEO Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $29.16, for a total value of $64,443.60. Following the sale, the chief executive officer directly owned 450,035 shares of the company’s stock, valued at $13,123,020.60. This represents a 0.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Abraham Ceesay also recently made the following trade(s):

• On Wednesday, October 7th, Abraham Ceesay sold 1,147 shares of Rapport Therapeutics stock. The shares were sold at an average price of $30.66, for a total transaction of $35,167.02.
• On Tuesday, October 6th, Abraham Ceesay sold 3,375 shares of Rapport Therapeutics stock. The shares were sold at an average price of $32.03, for a total value of $108,101.25.
• On Wednesday, September 23rd, Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock. The stock was sold at an average price of $39.17, for a total value of $86,565.70.
• On Tuesday, September 8th, Abraham Ceesay sold 8,210 shares of Rapport Therapeutics stock. The shares were sold at an average price of $45.61, for a total transaction of $374,458.10.
• On Tuesday, August 25th, Abraham Ceesay sold 18,921 shares of Rapport Therapeutics stock. The stock was sold at an average price of $49.57, for a total value of $937,913.97.
• On Tuesday, August 11th, Abraham Ceesay sold 28,958 shares of Rapport Therapeutics stock. The shares were sold at an average price of $48.01, for a total transaction of $1,390,273.58.
• On Monday, August 10th, Abraham Ceesay sold 22,541 shares of Rapport Therapeutics stock. The stock was sold at an average price of $46.26, for a total value of $1,042,746.66.
• On Monday, July 27th, Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock. The stock was sold at an average price of $42.11, for a total transaction of $93,063.10.

Rapport Therapeutics Trading Down 2.3%

RAPP stock opened at $25.93 on Friday. The firm has a market cap of $1.24 billion, a PE ratio of -8.53 and a beta of 1.22. The stock has a 50-day moving average price of $39.01 and a 200-day moving average price of $38.93. Rapport Therapeutics, Inc. has a 1-year low of $23.75 and a 1-year high of $52.93.

Rapport Therapeutics (NASDAQ:RAPP) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). On average, analysts forecast that Rapport Therapeutics, Inc. will post -4.08 earnings per share for the current year.

Trending Headlines about Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 met both Phase 2 endpoints in bipolar mania. The drug delivered statistically significant placebo-adjusted improvements in mania scores, and Rapport plans to advance it into Phase 3. Success could expand RAP-219’s opportunity beyond epilepsy and materially increase the company’s pipeline value. Rapport Therapeutics Phase 2 results
• Positive Sentiment: Analysts remain optimistic and raised price targets. JonesTrading lifted its target to $82, BTIG to $89 and Raymond James to $86, while HC Wainwright maintained a Buy rating. The reported consensus target of approximately $68.36 implies substantial upside from recent levels. Rapport Therapeutics analyst price target
• Positive Sentiment: Multiple insiders bought shares on the open market. CFO Troy Ignelzi purchased 5,500 shares, while directors Steven Paul, John Maraganore, Wendy Young, Paul Silva and Ramiro Sanchez also bought shares. The purchases totaled roughly $1.8 million based on the disclosed transactions and may signal management confidence following the clinical update. Rapport Therapeutics insider buying
• Neutral Sentiment: An analysis suggested Rapport could be significantly below estimated fair value following the Phase 2 results, but that valuation depends on successful Phase 3 development, regulatory approval and eventual commercialization.
• Negative Sentiment: Investors may have viewed the clinical win as less decisive than hoped. Reports indicated that some portions of the data only narrowly met expectations, potentially prompting profit-taking after the initial rally. Rapport bipolar mania data analysis
• Negative Sentiment: Rapport remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss missed analyst expectations, and analysts forecast a full-year loss of approximately $4.09 per share. CEO Abraham Ceesay also sold 2,210 shares, a relatively small reduction of 0.49% in his holdings, which contrasts with the broader insider buying. SEC CEO ownership filing

Wall Street Analysts Forecast Growth

RAPP has been the topic of several research analyst reports. Wolfe Research began coverage on Rapport Therapeutics in a research report on Thursday, October 15th. They issued an “outperform” rating and a $50.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $66.00 price objective on shares of Rapport Therapeutics in a report on Tuesday, October 20th. Wall Street Zen cut shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Wells Fargo & Company decreased their price target on Rapport Therapeutics from $51.00 to $50.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, Citigroup reiterated an “outperform” rating on shares of Rapport Therapeutics in a research report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Rapport Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $68.36.

Institutional Trading of Rapport Therapeutics

Large investors have recently modified their holdings of the business. KBC Group NV bought a new stake in shares of Rapport Therapeutics in the 1st quarter worth approximately $30,000. Sterling Capital Management LLC boosted its holdings in shares of Rapport Therapeutics by 597.9% during the 3rd quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock valued at $33,000 after buying an additional 843 shares in the last quarter. State of Wyoming purchased a new stake in shares of Rapport Therapeutics in the 2nd quarter worth about $65,000. Meeder Asset Management Inc. purchased a new stake in shares of Rapport Therapeutics in the 2nd quarter worth about $116,000. Finally, AlphaCentric Advisors LLC increased its stake in shares of Rapport Therapeutics by 6.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company’s stock worth $201,000 after acquiring an additional 408 shares in the last quarter.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.